共 143 条
[1]
Amori RE(2007)Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 298 194-206
[2]
Lau J(2012)Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ 344 e1369-2637
[3]
Pittas AG(2006)Sitagliptin Study 021 Group: effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 29 2632-483
[4]
Karagiannis T(2012)2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial Lancet 380 475-2317
[5]
Paschos P(2008)Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study Diabetes Care 31 2315-1146
[6]
Paletas K(2014)Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study BMJ 348 g2780-128
[7]
Matthews DR(2014)Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies BMJ 348 g2366-181
[8]
Tsapas A(1999)Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association Circulation 100 1134-1326
[9]
Aschner P(2013)Diabetes mellitus and its impact on long-term outcomes after coronary artery bypass graft surgery Acta Diabetol 50 123-1335
[10]
Kipnes MS(2011)The diabetic cardiomyopathy Acta Diabetol 48 173-2643